Strauss, 72,147 patient budesonide prophylaxis study: 24% lower mortality [p=0.01], 22% lower ICU admission [p=0.003], and 19% lower hospitalization [p<0.0001] https://c19p.org/strauss
copied to clipboard
Intranasal Corticosteroids Are Associated with Better Outcomes in Coronavirus Disease 2019
et al., The Journal of Allergy and Clinical Immunology: In Practice, doi:10.1016/j.jaip.2021.08.007
Retrospective 72,147 COVID-19+ patients in the USA, showing lower mortality, ICU admission, and hospitalization with intranasal corticosteroid use.
|
risk of death, 23.5% lower, RR 0.76, p = 0.01, treatment 231 of 10,187 (2.3%), control 1,649 of 61,960 (2.7%), NNT 254, adjusted per study, odds ratio converted to relative risk, PSM.
|
|
risk of ICU admission, 22.3% lower, RR 0.78, p = 0.003, treatment 376 of 10,187 (3.7%), control 2,559 of 61,960 (4.1%), adjusted per study, odds ratio converted to relative risk, PSM.
|
|
risk of hospitalization, 18.9% lower, RR 0.81, p < 0.001, treatment 1,676 of 10,187 (16.5%), control 10,932 of 61,960 (17.6%), adjusted per study, odds ratio converted to relative risk, PSM.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Strauss et al., 23 Aug 2021, retrospective, USA, peer-reviewed, 8 authors, study period 1 April, 2020 - 31 March, 2021.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.